The CRISPR Revolution
The development of CRISPR-Cas9, a programmable gene-editing tool adapted from a bacterial immune system, and its path from an unexplained DNA curiosity to a Nobel Prize and the first approved genetic-editing therapies. The technology transformed biology, agriculture, and medicine while opening an unresolved global debate over editing the human germline.
Events
Mysterious Repeats in E. coli
Yoshizumi Ishino and colleagues published the first description of unusual repeated DNA sequences in the bacterium E. coli, interspersed with short spacers of unknown origin. The sequences were noted as a curiosity; their function would remain a mystery for nearly two decades.
Location: Osaka, Japan
The Immune-Memory Hypothesis
Francisco Mojica and, independently, other researchers proposed that CRISPR spacers matched DNA of viruses that had attacked the microbes, implying the repeats stored a genetic memory of past infections. The hypothesis reframed the obscure sequences as the key to a bacterial adaptive immune system.
Location: Alicante, Spain
CRISPR Confirmed as an Immune System
Philippe Horvath and colleagues at the food-science company Danisco (later DuPont) experimentally demonstrated that bacteria use CRISPR sequences to acquire resistance to viruses that previously attacked them. The paper confirmed CRISPR as a functioning antiviral defense mechanism and prompted researchers to ask whether it could be redirected.
Location: DuPont, United States
Cas9 Reprogrammed as Genetic Scissors
Emmanuelle Charpentier and Jennifer Doudna's teams published in Science that the Cas9 protein could be programmed with a single guide RNA molecule to cut DNA at any chosen sequence. The discovery converted a bacterial immune trick into a programmable tool for editing the genomes of any organism.
Location: Berkeley, California, United States
CRISPR Enters Human Cells
Research groups led by Feng Zhang, George Church, and others, alongside Doudna's laboratory, reported within weeks of each other that CRISPR-Cas9 could edit the genomes of human cells. The simultaneous publications triggered a race to apply the tool across biology and a patent dispute between research institutions that continues to shape the industry around the technology.
Location: Cambridge, Massachusetts, United States
Embryo Editing Sparks a Global Ethics Debate
Chinese scientists reported editing the genomes of non-viable human embryos with CRISPR, the first such attempt, drawing immediate calls from the scientific community for restraint on germline editing. An international summit in Washington that December convened scientists and ethicists, and by year's end CRISPR had been named Science's Breakthrough of the Year amid an unresolved debate over where editing human heredity should stop.
Location: Guangzhou, China
The He Jiankui Affair
Chinese scientist He Jiankui announced that twin girls had been born from CRISPR-edited embryos, modified to resist HIV infection in an experiment he said was intended to protect the children. The claim, revealed on the eve of a genome-editing summit, drew condemnation from governments and scientific bodies worldwide; Chinese authorities sentenced him to prison in 2019 for violating medical regulations, leaving the question of heritable human editing legally closed but scientifically open.
Location: Hong Kong, China
Nobel Prize in Chemistry
The Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna for the development of CRISPR-Cas9 genome editing, one of the fastest science-to-Nobel recognitions in history. Other key contributors to the discovery, notably Virginijus Šikšnys and Feng Zhang's laboratory, were not included in the award, a decision widely discussed in the scientific community.
Location: Stockholm, Sweden
First CRISPR Therapy Approved
The UK medicines regulator approved Casgevy (exagamglogene autotemcel), a CRISPR-based treatment for sickle-cell disease and beta thalassemia, the first approved therapy built on CRISPR gene editing. The United States followed on December 8, 2023, converting the bacterial immune-system discovery into a medical treatment for patients with inherited blood disorders.
Location: London, United Kingdom